2021 EUGOGO临床实践指南：Graves眼病的药物治疗

2021-07-01 欧洲Graves' 眼病专家组 Eur J Endocrinol

本文主要针对GO的药物治疗提供指导建议。

中文标题：

英文标题：

THE 2021 EUROPEAN GROUP ON GRAVES' ORBITOPATHY (EUGOGO) CLINICAL PRACTICE GUIDELINES FOR THE MEDICAL MANAGEMENT OF GRAVES' ORBITOPATHY

发布机构：

欧洲Graves' 眼病专家组

发布日期：

2021-07-01

简要介绍：

2021年7月，欧洲Graves' 眼病专家组(EUGOGO)发布了Graves眼病的药物治疗指南，Graves眼病（GO）是Graves病的主要甲状腺外表现，其治疗的选择应基于对GO的临床活动度和严重程度的评估。本文主要针对GO的药物治疗提供指导建议。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=10e4b1c00220e91f, title=2021 EUGOGO临床实践指南：Graves眼病的药物治疗, enTitle=THE 2021 EUROPEAN GROUP ON GRAVES' ORBITOPATHY (EUGOGO) CLINICAL PRACTICE GUIDELINES FOR THE MEDICAL MANAGEMENT OF GRAVES' ORBITOPATHY, guiderFrom=Eur J Endocrinol, authorId=0, author=, summary=本文主要针对GO的药物治疗提供指导建议。, cover=https://img.medsci.cn/20211015/1634308331947_5579292.jpg, journalId=0, articlesId=null, associationId=2008, associationName=欧洲Graves' 眼病专家组, associationIntro=欧洲Graves' 眼病专家组(EUGOGO,European Group on Graves' Orbitopathy), copyright=0, guiderPublishedTime=Thu Jul 01 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年7月，欧洲Graves' 眼病专家组(EUGOGO)发布了Graves眼病的药物治疗指南，Graves眼病（GO）是Graves病的主要甲状腺外表现，其治疗的选择应基于对GO的临床活动度和严重程度的评估。本文主要针对GO的药物治疗提供指导建议。</span></p>, tagList=[TagDto(tagId=26062, tagName=Graves眼病)], categoryList=[CategoryDto(categoryId=32, categoryName=眼科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=26062, guiderKeyword=Graves眼病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6837, appHits=164, showAppHits=0, pcHits=754, showPcHits=6673, likes=1, shares=18, comments=12, approvalStatus=1, publishedTime=Fri Oct 15 23:31:43 CST 2021, publishedTimeString=2021-07-01, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Fri Oct 15 22:34:51 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 15:49:29 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=[1479683X - European Journal of Endocrinology] The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy.pdf)])

[1479683X - European Journal of Endocrinology] The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy.pdf

下载请点击：

评论区 (11)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=2113377, encodeId=e9b921133e702, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0562596408, createdName=er.ying, createdTime=Tue Feb 07 10:27:35 CST 2023, time=2023-02-07, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1209809, encodeId=a8b11209809f1, content=多谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2405453243, createdName=ms7000000239800838, createdTime=Sat Apr 09 14:43:34 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200658, encodeId=815f12006580f, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Tue Mar 08 20:31:39 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070560, encodeId=360a10e0560eb, content=感谢分享~, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb4a4883202, createdName=804824557, createdTime=Mon Nov 15 22:03:38 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074790, encodeId=8d3e10e47904d, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Sun Nov 28 16:17:33 CST 2021, time=2021-11-28, status=1, ipAttribution=)]
2023-02-07 er.ying 来自辽宁省

感谢分享

39 0
[GetPortalCommentsPageByObjectIdResponse(id=2113377, encodeId=e9b921133e702, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0562596408, createdName=er.ying, createdTime=Tue Feb 07 10:27:35 CST 2023, time=2023-02-07, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1209809, encodeId=a8b11209809f1, content=多谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2405453243, createdName=ms7000000239800838, createdTime=Sat Apr 09 14:43:34 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200658, encodeId=815f12006580f, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Tue Mar 08 20:31:39 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070560, encodeId=360a10e0560eb, content=感谢分享~, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb4a4883202, createdName=804824557, createdTime=Mon Nov 15 22:03:38 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074790, encodeId=8d3e10e47904d, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Sun Nov 28 16:17:33 CST 2021, time=2021-11-28, status=1, ipAttribution=)]
2022-04-09 ms7000000239800838

多谢

41 0
[GetPortalCommentsPageByObjectIdResponse(id=2113377, encodeId=e9b921133e702, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0562596408, createdName=er.ying, createdTime=Tue Feb 07 10:27:35 CST 2023, time=2023-02-07, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1209809, encodeId=a8b11209809f1, content=多谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2405453243, createdName=ms7000000239800838, createdTime=Sat Apr 09 14:43:34 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200658, encodeId=815f12006580f, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Tue Mar 08 20:31:39 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070560, encodeId=360a10e0560eb, content=感谢分享~, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb4a4883202, createdName=804824557, createdTime=Mon Nov 15 22:03:38 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074790, encodeId=8d3e10e47904d, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Sun Nov 28 16:17:33 CST 2021, time=2021-11-28, status=1, ipAttribution=)]
2022-03-08 245462683

感谢分享

49 0
[GetPortalCommentsPageByObjectIdResponse(id=2113377, encodeId=e9b921133e702, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0562596408, createdName=er.ying, createdTime=Tue Feb 07 10:27:35 CST 2023, time=2023-02-07, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1209809, encodeId=a8b11209809f1, content=多谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2405453243, createdName=ms7000000239800838, createdTime=Sat Apr 09 14:43:34 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200658, encodeId=815f12006580f, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Tue Mar 08 20:31:39 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070560, encodeId=360a10e0560eb, content=感谢分享~, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb4a4883202, createdName=804824557, createdTime=Mon Nov 15 22:03:38 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074790, encodeId=8d3e10e47904d, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Sun Nov 28 16:17:33 CST 2021, time=2021-11-28, status=1, ipAttribution=)]
2021-11-15 804824557

感谢分享~

63 1

展开1条回复
[GetPortalCommentsPageByObjectIdResponse(id=2113377, encodeId=e9b921133e702, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0562596408, createdName=er.ying, createdTime=Tue Feb 07 10:27:35 CST 2023, time=2023-02-07, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1209809, encodeId=a8b11209809f1, content=多谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2405453243, createdName=ms7000000239800838, createdTime=Sat Apr 09 14:43:34 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200658, encodeId=815f12006580f, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Tue Mar 08 20:31:39 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070560, encodeId=360a10e0560eb, content=感谢分享~, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb4a4883202, createdName=804824557, createdTime=Mon Nov 15 22:03:38 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074790, encodeId=8d3e10e47904d, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Sun Nov 28 16:17:33 CST 2021, time=2021-11-28, status=1, ipAttribution=)]
2021-11-28 245462683

谢谢分享

58 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

眼科指南

2021 EUGOGO临床实践指南：Graves眼病的药物治疗

相关指南

拓展阅读

科室

工具

服务